Zacks Investment Research upgraded shares of TherapeuticsMD (NASDAQ:TXMD) from a sell rating to a hold rating in a research report sent to investors on Saturday.
According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “
TXMD has been the subject of several other reports. BidaskClub upgraded shares of TherapeuticsMD from a strong sell rating to a sell rating in a research report on Wednesday, October 25th. Oppenheimer set a $10.00 target price on shares of TherapeuticsMD and gave the stock a buy rating in a report on Monday, October 16th. Cantor Fitzgerald reiterated a buy rating and set a $28.00 target price on shares of TherapeuticsMD in a report on Sunday, January 7th. Jefferies Group reiterated a buy rating and set a $15.00 target price on shares of TherapeuticsMD in a report on Tuesday, September 26th. Finally, Cowen reiterated an outperform rating and set a $16.00 target price (up from $13.00) on shares of TherapeuticsMD in a report on Monday, November 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $14.50.
TherapeuticsMD (TXMD) traded up $0.13 on Friday, reaching $6.30. The company had a trading volume of 2,562,847 shares, compared to its average volume of 1,431,696. The company has a market capitalization of $1,363.32, a PE ratio of -15.75 and a beta of 1.36. TherapeuticsMD has a 1-year low of $3.50 and a 1-year high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The business had revenue of $4.42 million during the quarter, compared to analyst estimates of $5.36 million. During the same period in the prior year, the business posted ($0.13) earnings per share. The company’s revenue was down 19.7% on a year-over-year basis. research analysts predict that TherapeuticsMD will post -0.37 EPS for the current fiscal year.
In other news, Director Tommy G. Thompson bought 5,000 shares of the company’s stock in a transaction dated Friday, December 8th. The stock was bought at an average cost of $6.21 per share, for a total transaction of $31,050.00. Following the completion of the acquisition, the director now owns 3,555 shares in the company, valued at approximately $22,076.55. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 23.92% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Amalgamated Bank increased its stake in shares of TherapeuticsMD by 7.2% during the second quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock valued at $104,000 after purchasing an additional 1,322 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of TherapeuticsMD by 3.9% during the second quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock valued at $114,000 after purchasing an additional 818 shares in the last quarter. Edge Wealth Management LLC increased its stake in shares of TherapeuticsMD by 2,500.0% during the fourth quarter. Edge Wealth Management LLC now owns 20,800 shares of the company’s stock valued at $125,000 after purchasing an additional 20,000 shares in the last quarter. Virtu KCG Holdings LLC bought a new position in shares of TherapeuticsMD during the second quarter valued at approximately $157,000. Finally, Quantbot Technologies LP bought a new position in shares of TherapeuticsMD during the third quarter valued at approximately $189,000. Institutional investors own 73.69% of the company’s stock.
WARNING: “TherapeuticsMD (TXMD) Upgraded to “Hold” by Zacks Investment Research” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/21/therapeuticsmd-txmd-upgraded-to-hold-by-zacks-investment-research.html.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.